@NP	Development	1
@NP	a tissue-engineered composite	16
@NP	traumatic paraplegia	67
@NP	rats Abstract This study was designed to assess a new composite	91
@NP	rats	91
@NP	Abstract This study	97
@NP	a new composite	140
@NP	regeneration of injured spinal cord	174
@NP	regeneration	174
@NP	injured spinal cord	190
@NP	paraplegic rats following complete cord transection	213
@NP	paraplegic rats	213
@NP	complete cord transection	239
@NP	Neuronal xenogeneic cells	266
@NP	biopsies of adult nasal olfactory mucosa -LRB- NOM -RRB- of human origin	297
@NP	biopsies	297
@NP	adult nasal olfactory mucosa -LRB- NOM -RRB- of human origin	309
@NP	adult nasal olfactory mucosa -LRB- NOM -RRB-	309
@NP	adult nasal olfactory mucosa	309
@NP	NOM	339
@NP	human origin	347
@NP	spinal cords of human embryos	364
@NP	spinal cords	364
@NP	human embryos	380
@NP	two consecutive stages	412
@NP	stationary cultures in a viscous semisolid gel -LRB- NVR-N-Gel -RRB-	436
@NP	stationary cultures	436
@NP	a viscous semisolid gel -LRB- NVR-N-Gel -RRB-	459
@NP	a viscous semisolid gel	459
@NP	NVR-N-Gel	484
@NP	suspension on positively charged microcarriers -LRB- MCs -RRB-	502
@NP	suspension	502
@NP	positively charged microcarriers -LRB- MCs -RRB-	516
@NP	positively charged microcarriers	516
@NP	MCs	550
@NP	A tissueengineered tubular scaffold	556
@NP	bundles of parallel nanofibers	604
@NP	bundles	604
@NP	parallel nanofibers	615
@NP	Both the tube and the nanofibers	651
@NP	the tube	656
@NP	the nanofibers	669
@NP	a biodegradable dextran sulphate -- gelatin co-precipitate	697
@NP	a biodegradable dextran sulphate	697
@NP	gelatin co-precipitate	730
@NP	The suturable scaffold	754
@NP	the	786
@NP	the site of injury	801
@NP	the site	801
@NP	injury	813
@NP	the regenerating axons	846
@NP	Implants of adult human NOM cells	870
@NP	Implants	870
@NP	adult human NOM cells	882
@NP	eight rats	924
@NP	a 4 mm segment of the spinal cord	947
@NP	a 4 mm segment	947
@NP	the spinal cord	965
@NP	Another four rats whose spinal cords had also been transected	1010
@NP	Another four rats	1010
@NP	spinal cords	1034
@NP	a composite	1092
@NP	human embryonic spinal cord cells	1124
@NP	Eight other cord-transected rats	1159
@NP	a control group	1202
@NP	Physiological and behavioral analysis , performed 3 months after implantation ,	1219
@NP	Physiological and behavioral analysis	1219
@NP	3 months	1268
@NP	implantation	1283
@NP	partial recovery	1306
@NP	function in one	1326
@NP	function	1326
@NP	one	1338
@NP	two limbs	1345
@NP	three	1358
@NP	eight animals of the NOM implanted group	1371
@NP	eight animals	1371
@NP	the NOM implanted group	1388
@NP	all the four rats	1419
@NP	human embryonic spinal cord cells	1471
@NP	Animals of the control group	1506
@NP	Animals	1506
@NP	the control group	1517
@NP	transmission of stimuli	1582
@NP	transmission	1582
@NP	stimuli	1598
@NP	the brain	1609
@NP	The utilization of an innovative composite	1620
@NP	The utilization	1620
@NP	an innovative composite	1639
@NP	a gap resulting from the transection and removal of a 4 mm	1681
@NP	a gap	1681
@NP	the transection and removal of a 4 mm	1702
@NP	the transection and removal	1702
@NP	a 4 mm	1733
@NP	spinal cord segment	1740
@NP	promise	1766
@NP	the feasibility	1786
@NP	this approach for partial reconstruction of spinal cord lesions	1805
@NP	this approach	1805
@NP	partial reconstruction of spinal cord lesions	1823
@NP	partial reconstruction	1823
@NP	spinal cord lesions	1849
@NP	Such an	1870
@NP	a vital bridging station in acute and chronic cases of paraplegia	1899
@NP	a vital bridging station	1899
@NP	acute and chronic cases	1927
@NP	paraplegia	1954
@NP	Introduction Spinal cord injuries involving partial or complete transection	1967
@NP	Introduction Spinal cord injuries	1967
@NP	Introduction	1967
@NP	Spinal cord injuries	1980
@NP	partial or complete transection	2011
@NP	other lesions in the central nervous system	2052
@NP	other lesions	2052
@NP	the central nervous system	2069
@NP	their own	2119
@NP	Complete spinal cord injuries in humans and other mammals	2130
@NP	Complete spinal cord injuries	2130
@NP	humans and other mammals	2163
@NP	humans	2163
@NP	other mammals	2174
@NP	loss of sensory , motor and , reflex functions below the site of injury	2194
@NP	loss of sensory	2194
@NP	loss	2194
@NP	sensory	2202
@NP	motor	2211
@NP	reflex functions below the site of injury	2222
@NP	reflex functions	2222
@NP	the site of injury	2245
@NP	the site	2245
@NP	injury	2257
@NP	Several different approaches	2265
@NP	an injured spinal cord	2338
@NP	The use	2362
@NP	growth factors	2373
@NP	exogenous administration	2399
@NP	-LSB- 8 , 14 , 36	2424
@NP	growth factor-treated implants	2454
@NP	-LSB- 22 , 23 , 39 -RSB-	2485
@NP	genetically engineered cells	2502
@NP	-LSB- 34 , 46	2531
@NP	limited success	2565
@NP	Others	2582
@NP	their efforts on the use of various tissue-engineered scaffolds	2607
@NP	their efforts	2607
@NP	the use of various tissue-engineered scaffolds	2624
@NP	the use	2624
@NP	various tissue-engineered scaffolds	2635
@NP	-LSB- 4 , 54 , 57 -RSB-	2671
@NP	Spinal cord reconstruction using implantation of cells from various sources	2684
@NP	Spinal cord reconstruction	2684
@NP	implantation of cells from various sources	2717
@NP	implantation	2717
@NP	cells from various sources	2733
@NP	cells	2733
@NP	various sources	2744
@NP	momentum	2777
@NP	recent years	2789
@NP	-LSB- 28 , 41 -RSB-	2802
@NP	one of the major disadvantages of the implantation or injection of cells	2821
@NP	one	2821
@NP	the major disadvantages of the implantation or injection of cells	2828
@NP	the major disadvantages	2828
@NP	the implantation or injection of cells	2855
@NP	the implantation or injection	2855
@NP	cells	2888
@NP	the limited viable cell survival after the procedure	2903
@NP	the limited viable cell survival	2903
@NP	the procedure	2942
@NP	cells	2960
@NP	the injury site	2981
@NP	One feasible innovative way of repairing injured mammalian spinal cord	2998
@NP	One feasible innovative way	2998
@NP	injured mammalian spinal cord	3039
@NP	a composite	3084
@NP	cells	3129
@NP	an autologous or allogeneic source	3140
@NP	The implanted cells	3176
@NP	a vital bridge to connect the stumps of the severed spinal cords -LSB- 44 -RSB-	3214
@NP	the stumps of the severed spinal cords -LSB- 44 -RSB-	3240
@NP	the stumps	3240
@NP	the severed spinal cords -LSB- 44 -RSB-	3254
@NP	the severed spinal cords	3254
@NP	44 -RSB-	3280
@NP	Such a composite spinal cord	3285
@NP	a combination	3331
@NP	the various elements	3348
@NP	the healing process	3382
@NP	a tissue-engineered scaffold to anchor the implanted cells	3411
@NP	the implanted cells	3450
@NP	a viscous adhesive milieu	3493
@NP	a variety of factors -LSB- 47 -RSB-	3538
@NP	a variety	3538
@NP	factors -LSB- 47 -RSB-	3551
@NP	factors	3551
@NP	47 -RSB-	3560
@NP	The dream	3565
@NP	primordial cells	3584
@NP	early human embryos for implantation therapy in spinal cord injuries	3606
@NP	early human embryos	3606
@NP	implantation therapy in spinal cord injuries	3630
@NP	implantation therapy	3630
@NP	spinal cord injuries	3654
@NP	a step	3682
@NP	reality	3699
@NP	-LSB- 27 , 37 -RSB-	3707
@NP	Recent discoveries	3717
@NP	the potential	3743
@NP	isolation and cultivation	3761
@NP	human embryonic stem cells	3790
@NP	49 -RSB-	3818
@NP	their differentiation in culture to neurons and other cell types -LSB- 43 , 49	3827
@NP	their differentiation	3827
@NP	culture to neurons and other cell types -LSB- 43 , 49	3852
@NP	culture	3852
@NP	neurons and other cell types	3863
@NP	neurons	3863
@NP	other cell types	3875
@NP	-LSB- 43 , 49	3892
@NP	viable treatment of spinal cord injuries using such human embryonic stem cells	3915
@NP	viable treatment	3915
@NP	spinal cord injuries using such human embryonic stem cells	3935
@NP	spinal cord injuries	3935
@NP	such human embryonic stem cells	3962
@NP	an allogeneic graft	4017
@NP	the risks	4058
@NP	rejection , immunogenic reaction and possible neoplastic transformation	4071
@NP	rejection	4071
@NP	immunogenic reaction	4082
@NP	possible neoplastic transformation	4107
@NP	An excellent autologous source of adult neuronal precursor cells	4143
@NP	An excellent autologous source	4143
@NP	adult neuronal precursor cells	4177
@NP	the nasal olfactory mucosa -LRB- NOM -RRB-	4211
@NP	the nasal olfactory mucosa	4211
@NP	NOM	4239
@NP	The NOM tissue	4245
@NP	the neurons and the sustentacular cells of the NOM	4283
@NP	the neurons	4283
@NP	the sustentacular cells of the NOM	4299
@NP	the sustentacular cells	4299
@NP	the NOM	4326
@NP	themselves	4340
@NP	life by proliferation of the basal global stem cells -LSB- 9 , 15	4369
@NP	life	4369
@NP	proliferation of the basal global stem cells -LSB- 9 , 15	4377
@NP	proliferation	4377
@NP	the basal global stem cells	4394
@NP	-LSB- 9 , 15	4422
@NP	45	4430
@NP	the unique sensory characteristics of the NOM neurons	4445
@NP	the unique sensory characteristics	4445
@NP	the NOM neurons	4483
@NP	them	4506
@NP	signals as a	4551
@NP	signals	4551
@NP	a	4562
@NP	relay station '' in the spinal cord	4566
@NP	relay station	4566
@NP	the spinal cord	4585
@NP	The scaffolds	4602
@NP	tissue-engineering technologies for spinal cord implantation	4628
@NP	tissue-engineering technologies	4628
@NP	spinal cord implantation	4664
@NP	synthetic and naturally occurring polymeric macromolecules	4710
@NP	synthetic	4710
@NP	naturally occurring polymeric macromolecules	4724
@NP	The naturally occurring ones	4770
@NP	protein-peptides-based scaffolds and carbohydrates	4825
@NP	scaffolds	4883
@NP	-LSB- 26 , 29 , 52 -RSB-	4893
@NP	There	4907
@NP	several published examples	4917
@NP	the scaffold	4950
@NP	the extracellular matrix -LRB- ECM -RRB- present in connective tissues	4972
@NP	the extracellular matrix -LRB- ECM -RRB-	4972
@NP	the extracellular matrix	4972
@NP	ECM	4998
@NP	connective tissues	5014
@NP	collagens and proteoglycans	5042
@NP	-LSB- 55 , 59 , 60 -RSB-	5070
@NP	The latter type best	5084
@NP	The latter type	5084
@NP	best	5100
@NP	the ECM constituents of many tissues , including that of the spinal cord	5113
@NP	the ECM constituents	5113
@NP	many tissues	5137
@NP	that of the spinal cord	5161
@NP	that	5161
@NP	the spinal cord	5169
@NP	Other promising strategies	5186
@NP	a receptive environment for regeneration	5231
@NP	a receptive environment	5231
@NP	regeneration	5259
@NP	the myelin-associated inhibitors of axonal growth	5286
@NP	the myelin-associated inhibitors	5286
@NP	axonal growth	5322
@NP	the physical and biochemical barrier , the so-called `` glial scar ''	5340
@NP	the physical and biochemical barrier	5340
@NP	the so-called `` glial scar ''	5378
@NP	-LSB- 7 , 17 , 40 , 48 , 53 -RSB-	5407
@NP	Last , but not the least important ,	5428
@NP	Last	5428
@NP	not the least important	5438
@NP	not the	5438
@NP	the intercellular viscous adhesive milieu	5466
@NP	its ingredients for supporting the vitality of the neuronal bridge	5512
@NP	its ingredients	5512
@NP	the vitality of the neuronal bridge	5543
@NP	the vitality	5543
@NP	the neuronal bridge	5559
@NP	The ECM ground substances of the spinal cord	5580
@NP	The ECM ground substances	5580
@NP	the spinal cord	5609
@NP	the consistency of colloidal-gels	5630
@NP	the consistency	5630
@NP	colloidal-gels	5649
@NP	several types of gels	5677
@NP	several types	5677
@NP	gels	5694
@NP	injured spinal cord	5732
@NP	-LSB- 34 , 56 , 57 -RSB-	5752
@NP	the current study	5769
@NP	we	5787
@NP	the development of an innovative composite	5800
@NP	the development	5800
@NP	an innovative composite	5819
@NP	a vital bridging station	5872
@NP	acute and chronic cases	5900
@NP	spinal transection or injury	5927
@NP	Materials and methods The composite	5958
@NP	Materials	5958
@NP	methods The composite	5972
@NP	methods	5972
@NP	The composite	5980
@NP	elements	6002
@NP	The scaffold	6011
@NP	NVRs tissue-engineered technology -LRB- patent pending -RRB- , consisting of two	6036
@NP	NVRs tissue-engineered technology	6036
@NP	NVRs	6036
@NP	tissue-engineered technology	6041
@NP	patent pending	6071
@NP	patent	6071
@NP	two	6102
@NP	biological cross-linked polymers	6126
@NP	It	6160
@NP	a tubular format	6167
@NP	a customized diameter of 2 mm and a wall thickness of 0.4 mm	6189
@NP	a customized diameter of 2 mm	6189
@NP	a customized diameter	6189
@NP	2 mm	6214
@NP	a wall thickness of 0.4 mm	6223
@NP	a wall thickness	6223
@NP	0.4 mm	6243
@NP	addition	6254
@NP	the tubular scaffold	6264
@NP	a bundle	6294
@NP	parallel nanofibers 50 -- 100 µm in diameter	6306
@NP	parallel nanofibers 50	6306
@NP	parallel nanofibers	6306
@NP	50	6326
@NP	100 µm in diameter	6330
@NP	100 µm	6330
@NP	diameter	6340
@NP	the same material as the scaffold -LRB- Fig. 1 -RRB-	6358
@NP	the same material	6358
@NP	the scaffold -LRB- Fig. 1 -RRB-	6379
@NP	the scaffold	6379
@NP	Fig. 1	6393
@NP	a series of preliminary experiments	6405
@NP	a series	6405
@NP	preliminary experiments	6417
@NP	the scaffold	6441
@NP	data not shown	6518
@NP	data	6518
@NP	The tube	6535
@NP	it	6575
@NP	a period of more than 3 months	6591
@NP	a period	6591
@NP	more than 3 months	6603
@NP	biodegradation	6628
@NP	place -LRB- data not shown -RRB-	6649
@NP	place	6649
@NP	data not shown	6656
@NP	data	6656
@NP	NVR-N-Gel	6673
@NP	a proprietary product of NVR Labs -LRB- patent pending -RRB-	6693
@NP	a proprietary product	6693
@NP	NVR Labs -LRB- patent pending -RRB-	6718
@NP	NVR Labs	6718
@NP	patent pending	6728
@NP	patent	6728
@NP	a crosslinked hyaluronic acid with the adhesive molecule laminin	6760
@NP	a	6760
@NP	hyaluronic acid	6774
@NP	the adhesive molecule laminin	6795
@NP	the following mixture	6830
@NP	ingredients	6855
@NP	antioxidants , neuronal growth factor	6868
@NP	antioxidants	6868
@NP	neuronal growth factor	6882
@NP	neuro-protective factors	6906
@NP	EGF , bFGF , BDNF and NGF	6932
@NP	20	6956
@NP	50 ng/ml , IGF-I	6959
@NP	50 ng/ml	6959
@NP	IGF-I	6969
@NP	50 ng/ml , LIF	6975
@NP	50 ng/ml	6975
@NP	LIF	6985
@NP	0.5 u/ml , NAC -LRB- n-acetyl cystein -RRB-	6989
@NP	0.5 u/ml	6989
@NP	NAC -LRB- n-acetyl cystein -RRB-	6999
@NP	NAC	6999
@NP	n-acetyl cystein	7004
@NP	10 µM , pifithrin a , cyclic	7023
@NP	10 µM , pifithrin a ,	7023
@NP	10 µM	7023
@NP	pifithrin a	7030
@NP	200 nM , and retinoic acid	7050
@NP	200 nM	7050
@NP	retinoic acid	7062
@NP	1	7076
@NP	5 µM	7078
@NP	The NVR-N-Gel	7084
@NP	polar and non-polar -LRB- hydrophobic -RRB- residues	7135
@NP	all	7179
@NP	cell cultivation	7220
@NP	the gel	7238
@NP	a concentration of 0.7 -- 1 % hyaluronic acid , however	7257
@NP	a concentration of 0.7	7257
@NP	a concentration	7257
@NP	0.7	7276
@NP	1 % hyaluronic acid , however	7280
@NP	1 %	7280
@NP	hyaluronic acid	7282
@NP	implantation	7312
@NP	a more viscous gel -LRB- 1.2 -- 1.5 % -RRB-	7325
@NP	a more viscous gel	7325
@NP	1.2 -- 1.5 %	7345
@NP	1.2	7345
@NP	1.5 %	7349
@NP	Cultivation	7364
@NP	adult human NOM and embryonic spinal cord cells Biopsies	7379
@NP	adult human olfactory nasal mucosa	7439
@NP	embryonic spinal cords of aborted fetuses	7478
@NP	embryonic spinal cords	7478
@NP	aborted fetuses	7504
@NP	16	7521
@NP	23 weeks of gestation	7524
@NP	23 weeks	7524
@NP	gestation	7536
@NP	cell isolation and the establishment of cultures	7566
@NP	cell isolation	7566
@NP	the establishment of cultures	7585
@NP	the establishment	7585
@NP	cultures	7606
@NP	The study with human derived samples	7616
@NP	The study	7616
@NP	human derived samples	7631
@NP	the Helsinki committee of Assaf-Harofeh Medical Center -LRB- no. 13/03 -RRB-	7669
@NP	the Helsinki committee	7669
@NP	Assaf-Harofeh Medical Center -LRB- no. 13/03 -RRB-	7695
@NP	Assaf-Harofeh Medical Center	7695
@NP	no. 13/03	7725
@NP	Informed consent	7737
@NP	each patient	7772
@NP	An innovative culture technique	7786
@NP	the scheme -LRB- Fig. 2 -RRB-	7848
@NP	the scheme	7848
@NP	Fig. 2	7860
@NP	It	7869
@NP	stationary cultures in gel	7881
@NP	stationary cultures	7881
@NP	gel	7904
@NP	cells	7926
@NP	suspension	7941
@NP	an anion exchange	7955
@NP	cylindrical , DEAE-cellulose -LRB- DE-53 -RRB- microcarriers -LRB- MCs -RRB-	7993
@NP	cylindrical , DEAE-cellulose -LRB- DE-53 -RRB- microcarriers	7993
@NP	cylindrical , DEAE-cellulose -LRB- DE-53 -RRB-	7993
@NP	microcarriers	8029
@NP	MCs	8044
@NP	Whatman	8050
@NP	England	8059
@NP	The MCs	8069
@NP	phosphate buffered saline -LRB- PBS -RRB- pH 7.4	8099
@NP	phosphate buffered saline -LRB- PBS -RRB-	8099
@NP	phosphate buffered saline	8099
@NP	PBS	8126
@NP	batches of 15 g in 100 ml PBS	8156
@NP	batches	8156
@NP	15 g in 100 ml PBS	8167
@NP	15 g	8167
@NP	100 ml PBS	8175
@NP	-LSB- 19 , 51 -RSB-	8186
@NP	The dissociated cells	8196
@NP	The	8196
@NP	cells	8212
@NP	suspension attached to the MCs for periods of 1 -- 4 weeks	8232
@NP	suspension	8232
@NP	the MCs for periods of 1 -- 4 weeks	8255
@NP	the MCs	8255
@NP	periods of 1 -- 4 weeks	8267
@NP	periods of 1	8267
@NP	periods	8267
@NP	1	8278
@NP	4 weeks	8280
@NP	various times during their growth period in suspension	8292
@NP	various times	8292
@NP	their growth period in suspension	8313
@NP	their growth period	8313
@NP	suspension	8336
@NP	cell-MC aggregates	8348
@NP	NVR-N-Gel as stationary cultures	8398
@NP	NVR-N-Gel	8398
@NP	stationary cultures	8411
@NP	The following growth media	8432
@NP	modified NEP medium	8470
@NP	the Bottenstein and Sato -LSB- 6 -RSB- N2 medium or M-21 medium	8499
@NP	the Bottenstein and Sato	8499
@NP	6 -RSB- N2 medium or M-21 medium	8525
@NP	The NEP medium	8554
@NP	DMEM-F12	8578
@NP	Invitrogen	8588
@NP	UK	8600
@NP	N2 additives	8605
@NP	progesterone , putresine , selenium , insulin and transferrin	8619
@NP	progesterone	8619
@NP	putresine , selenium , insulin and transferrin	8633
@NP	complex B27 supplements -LRB- Invitrogen -RRB- and 1 % BSA	8684
@NP	complex B27 supplements -LRB- Invitrogen -RRB-	8684
@NP	complex B27 supplements	8684
@NP	Invitrogen	8709
@NP	1 % BSA	8725
@NP	The M-21 medium	8733
@NP	NEP medium	8761
@NP	that B27	8780
@NP	100 µM	8804
@NP	nonessential amino acids , 30 ng/ml triiodothyronine	8811
@NP	nonessential amino acids	8811
@NP	30 ng/ml triiodothyronine	8837
@NP	1 mM sodium pyruvate	8868
@NP	Both media	8900
@NP	the same factors used to enrich the gel	8934
@NP	the same factors	8934
@NP	the gel	8966
@NP	cell expansion	8979
@NP	the media	8995
@NP	10 % fetal calf serum -LRB- FCS -RRB-	9024
@NP	10 % fetal calf serum	9024
@NP	FCS	9046
@NP	growth differentiation and implantation	9056
@NP	the serum	9096
@NP	the media	9123
@NP	Cells	9134
@NP	3	9166
@NP	4 weeks	9168
@NP	implantation	9185
@NP	Surgical and transplantation procedure The study	9199
@NP	Surgical	9199
@NP	transplantation procedure The study	9212
@NP	transplantation procedure	9212
@NP	The study	9238
@NP	the local ethical committee for experiments in laboratory animals	9266
@NP	the local ethical committee	9266
@NP	experiments in laboratory animals	9298
@NP	experiments	9298
@NP	laboratory animals	9313
@NP	Animal treatment and maintenance	9333
@NP	Animal treatment	9333
@NP	maintenance	9354
@NP	accordance	9374
@NP	the	9390
@NP	the care and use of animals '' , Institute of laboratory animal resources	9406
@NP	the care and use	9406
@NP	animals '' , Institute of laboratory animal resources	9426
@NP	animals	9426
@NP	Institute of laboratory animal resources	9437
@NP	Institute	9437
@NP	laboratory animal resources	9450
@NP	life sciences	9492
@NP	National Research Council	9507
@NP	National Academy Press	9534
@NP	Washington	9558
@NP	DC	9570
@NP	1966	9574
@NP	The DHEW publication no.	9580
@NP	80 -LRB- NIH -RRB-	9605
@NP	80	9605
@NP	NIH	9609
@NP	Office of Science and Health reports	9614
@NP	Office	9614
@NP	Science and Health reports	9624
@NP	DRR/NIH , Bethesda	9651
@NP	DRR/NIH	9651
@NP	Bethesda	9660
@NP	MD 20205	9670
@NP	USA	9680
@NP	Twenty Sprague-Dawly rats , 3-months old , each weighing approximately 250 g ,	9685
@NP	Twenty Sprague-Dawly rats	9685
@NP	each weighing approximately 250 g	9726
@NP	each	9726
@NP	approximately 250 g	9740
@NP	All rats	9772
@NP	intraperitoneal injections	9802
@NP	the operations	9834
@NP	anesthesia	9850
@NP	Ketamine HCL -LRB- 50501 USA -RRB- 125	9874
@NP	Ketamine HCL	9874
@NP	50501 USA	9888
@NP	125	9899
@NP	130 mg/kg and Xylosine -LRB- B2370 Belgium -RRB- 4.8 mg/kg	9903
@NP	130 mg/kg	9903
@NP	Xylosine -LRB- B2370 Belgium -RRB- 4.8 mg/kg	9917
@NP	Xylosine	9917
@NP	B2370 Belgium	9927
@NP	4.8 mg/kg	9942
@NP	electrophysiological tests	9957
@NP	rats	9985
@NP	a short period -LRB- 30 min -RRB- with Ketamine 75	10012
@NP	a short period -LRB- 30 min -RRB-	10012
@NP	a short period	10012
@NP	30 min	10028
@NP	Ketamine 75	10041
@NP	85 mg/kg and Xylosine 3 mg/kg	10053
@NP	85 mg/kg	10053
@NP	Xylosine 3 mg/kg	10066
@NP	removal of stitches	10088
@NP	removal	10088
@NP	stitches	10099
@NP	light anesthesia	10109
@NP	50 mg/kg Ketamine and 1.8 mg/kg Xylosine	10136
@NP	50 mg/kg Ketamine	10136
@NP	1.8 mg/kg Xylosine	10158
@NP	All the treatments and the	10178
@NP	All the treatments	10178
@NP	the	10201
@NP	tests were performed in a double blind randomized manner	10215
@NP	tests	10215
@NP	a double blind randomized manner	10239
@NP	All surgical procedures	10273
@NP	anesthetized rats	10315
@NP	a high magnification navigator microscope -LRB- Zeiss NC-4 -RRB-	10340
@NP	a high magnification navigator microscope	10340
@NP	Zeiss NC-4	10383
@NP	a class 100 animal operating room	10398
@NP	a class	10398
@NP	100 animal operating room	10406
@NP	The spinal cord	10433
@NP	a dorsal approach	10465
@NP	The overlying muscles	10484
@NP	T7 -- T8 laminae	10522
@NP	T7	10522
@NP	T8 laminae	10525
@NP	the spinal cord	10545
@NP	micro-scissors	10593
@NP	a 4 mm segment of the cord	10612
@NP	a 4 mm segment	10612
@NP	the cord	10630
@NP	A 4 mm gap	10652
@NP	the gap size formed after removal of the scar in chronic spinal cord injuries	10683
@NP	the gap size	10683
@NP	removal of the scar in chronic spinal cord injuries	10709
@NP	removal	10709
@NP	the scar in chronic spinal cord injuries	10720
@NP	the scar	10720
@NP	chronic spinal cord injuries	10732
@NP	Eight	10762
@NP	the 20 rats	10771
@NP	spinal cord transection and the removal of a 4 mm spinal cord segment	10797
@NP	spinal cord transection	10797
@NP	the removal of a 4 mm spinal cord segment	10825
@NP	the removal of a 4 mm	10825
@NP	the removal	10825
@NP	a 4 mm	10840
@NP	spinal cord segment	10847
@NP	no further treatment -LRB- sham treated control group -RRB-	10885
@NP	no further treatment	10885
@NP	sham treated control group	10907
@NP	sham	10907
@NP	control group	10920
@NP	The remaining 12 rats	10936
@NP	implantation of one of the composite implants	10968
@NP	implantation	10968
@NP	one	10984
@NP	the composite implants	10991
@NP	Eight rats	11015
@NP	implants containing NOM cells -LRB- Fig. 3 -RRB- and four rats	11044
@NP	implants	11044
@NP	NOM cells -LRB- Fig. 3 -RRB- and four rats	11064
@NP	NOM cells	11064
@NP	Fig. 3	11075
@NP	four rats	11087
@NP	human embryonal spinal cord-derived cells	11106
@NP	Embryonic human spinal cord cells	11149
@NP	as long term cultures	11194
@NP	the stage of myelin formation -LRB- Fig. 4 -RRB-	11219
@NP	the stage	11219
@NP	myelin formation -LRB- Fig. 4 -RRB-	11232
@NP	myelin formation	11232
@NP	Fig. 4	11250
@NP	1 -- 2 · 106 NOM or spinal cord cells	11265
@NP	1 -- 2 · 106 NOM	11265
@NP	1 -- 2	11265
@NP	· 106 NOM	11269
@NP	spinal cord cells	11282
@NP	NVR-N-Gel	11313
@NP	NVR scaffold	11344
@NP	the site of the excised spinal cord segment	11378
@NP	the site	11378
@NP	the excised spinal cord segment	11390
@NP	the	11390
@NP	spinal cord segment	11402
@NP	Four-millimeter long composite implants	11423
@NP	the transected area of the spinal cord , in direct contact	11478
@NP	the transected area	11478
@NP	the spinal cord	11501
@NP	direct contact	11521
@NP	the margins of the two stumps	11541
@NP	the margins	11541
@NP	the two stumps	11556
@NP	The entire area of the lesion containing the implant	11572
@NP	The entire area	11572
@NP	the lesion containing the implant	11591
@NP	the lesion	11591
@NP	the	11613
@NP	a thin biodegradable membrane	11642
@NP	the biological copolymer	11684
@NP	a few interstitial sutures	11722
@NP	fixation of the implants at the desired sites	11753
@NP	fixation	11753
@NP	the implants at the desired sites	11765
@NP	the implants	11765
@NP	the desired sites	11781
@NP	the muscular and cutaneous planes	11809
@NP	Post-operative animal maintenance	11868
@NP	the post-operative management of the animals care	11905
@NP	the post-operative management	11905
@NP	the animals care	11938
@NP	discomfort and pain	11977
@NP	implantation	12008
@NP	the rats	12021
@NP	urination and defecation	12047
@NP	the help of a veterinarian	12077
@NP	the help	12077
@NP	a veterinarian	12089
@NP	Animals	12118
@NP	ventilated cages , containing sterile sawdust and sterile food	12145
@NP	ventilated cages	12145
@NP	sterile sawdust and sterile food	12174
@NP	sterile sawdust	12174
@NP	sterile food	12194
@NP	The paraplegic rats	12208
@NP	solitary in cages	12238
@NP	solitary	12238
@NP	cages	12250
@NP	groups for 1 h every day	12278
@NP	groups	12278
@NP	1 h every day	12289
@NP	1 h	12289
@NP	every day	12293
@NP	a large facility	12307
@NP	the termination of the experiments	12328
@NP	the termination	12328
@NP	the experiments	12347
@NP	the animals	12364
@NP	general anesthesia	12398
@NP	Electrophysiological measurements	12418
@NP	Somatosensory	12452
@NP	potentials	12473
@NP	SSEP	12485
@NP	the experimental and control groups in a blinded manner	12508
@NP	the experimental and control groups	12508
@NP	a blinded manner	12547
@NP	3 months	12597
@NP	Conductivity of the spinal cord	12613
@NP	Conductivity	12613
@NP	the spinal cord	12629
@NP	stimulation	12660
@NP	the sciatic nerve and recording from two disc-recording electrodes	12675
@NP	the sciatic nerve and recording	12675
@NP	two disc-recording electrodes	12712
@NP	the rats ' scalps	12775
@NP	the rats '	12775
@NP	These electrodes , with conductive jelly ,	12793
@NP	These electrodes	12793
@NP	conductive jelly	12816
@NP	the scalp	12851
@NP	the somatosensory cortex	12873
@NP	the midline and reference electrode between the two eyes	12901
@NP	the midline and reference electrode	12901
@NP	the two eyes	12945
@NP	The earth electrode	12959
@NP	the thigh	12993
@NP	the side of the stimulation	13007
@NP	the side	13007
@NP	the stimulation	13019
@NP	The sciatic nerve	13036
@NP	a bipolar stimulating electrode	13072
@NP	Two hundred and fifty-six stimulation pulses of 0.1 ms in duration	13105
@NP	Two hundred and fifty-six stimulation pulses	13105
@NP	0.1 ms in duration	13153
@NP	0.1 ms	13153
@NP	duration	13163
@NP	a rate of 3 s -RRB-	13190
@NP	a rate	13190
@NP	3 s	13200
@NP	1	13204
@NP	The stimulus intensity	13207
@NP	slight twitching of the limb	13261
@NP	slight twitching	13261
@NP	the limb	13281
@NP	The appearance	13300
@NP	potentials	13325
@NP	a response to stimulation in two consecutive tests	13340
@NP	a response	13340
@NP	stimulation in two consecutive tests	13354
@NP	stimulation	13354
@NP	two consecutive tests	13369
@NP	Latency and amplitude -LRB- positive -- P wave peak -RRB-	13417
@NP	Latency and amplitude	13417
@NP	positive -- P wave peak	13440
@NP	positive	13440
@NP	P wave peak	13449
@NP	The rats	13476
@NP	diluted Nembutal	13526
@NP	15 mg/kg weight	13543
@NP	The test	13560
@NP	the Medelec/Teca Sapphire 4 ME electromyography apparatus	13589
@NP	20 Hz	13648
@NP	2 KHz band pass	13654
@NP	filter and calibration sensitivity 10 -- 20 mcV/div and time base 5 ms/div	13670
@NP	filter and calibration sensitivity 10	13670
@NP	filter and calibration sensitivity	13670
@NP	10	13705
@NP	20 mcV/div and time base 5 ms/div	13708
@NP	20 mcV/div	13708
@NP	time base 5 ms/div	13723
@NP	time base	13723
@NP	5 ms/div	13733
@NP	Locomotor rating scale The BBB scale -LSB- 5 -RSB-	13744
@NP	Locomotor rating scale	13744
@NP	The BBB scale	13767
@NP	5 -RSB-	13782
@NP	the locomotor rating scale	13795
@NP	0 -LRB- absent performance -RRB-	13835
@NP	0	13835
@NP	absent performance	13838
@NP	21 -LRB- complete normal gait performance -RRB-	13861
@NP	21	13861
@NP	complete normal gait performance	13865
@NP	This grading scale	13900
@NP	behavioral recovery and gait performance weekly for 2	13938
@NP	behavioral recovery and gait performance weekly	13938
@NP	2	13990
@NP	10 months after spinal cord injury	13992
@NP	10 months	13992
@NP	spinal cord injury	14008
@NP	Magnetic resonance imaging -LRB- MRI -RRB- analysis Sample preparation	14028
@NP	Magnetic resonance imaging	14028
@NP	MRI	14056
@NP	analysis Sample preparation	14061
@NP	spinal cords were excised and fixed with formalin	14090
@NP	spinal cords	14090
@NP	formalin	14131
@NP	The spinal cords	14141
@NP	5 mm NMRtubes with their long axis parallel	14177
@NP	5 mm NMRtubes	14177
@NP	their long axis parallel	14196
@NP	the z-direction -LRB- the Bo direction -RRB- of the magnet	14224
@NP	the z-direction -LRB- the Bo direction -RRB-	14224
@NP	the z-direction	14224
@NP	the Bo direction	14241
@NP	the magnet	14262
@NP	Fluorinert -LRB- Sigma Chemical Co. , St.	14289
@NP	Fluorinert	14289
@NP	Sigma Chemical Co.	14301
@NP	St.	14321
@NP	Louis , MO , USA -RRB- .	14325
@NP	Louis	14325
@NP	USA	14336
@NP	The temperature in the magnet	14342
@NP	The temperature	14342
@NP	the magnet	14361
@NP	25.0 ±	14390
@NP	0.1 C for the duration of the experiments	14395
@NP	0.1 C	14395
@NP	the duration of the experiments	14405
@NP	the duration	14405
@NP	the experiments	14421
@NP	The MRI diffusion experiments	14438
@NP	a wide-bore 8.4 T NMR spectrometer	14486
@NP	Bruker	14521
@NP	Karlsruhe	14529
@NP	Germany	14540
@NP	a micro5 imaging gradient probe capable of producing pulse gradients	14563
@NP	a micro5 imaging gradient probe	14563
@NP	pulse gradients	14616
@NP	up to 190 G cm	14635
@NP	190	14641
@NP	1	14650
@NP	each of the three directions	14655
@NP	each	14655
@NP	the three directions	14663
@NP	Diffusion	14685
@NP	MR images	14704
@NP	the stimulated	14735
@NP	diffusion imaging pulse sequence with the following parameters	14755
@NP	diffusion imaging pulse sequence	14755
@NP	the following parameters	14793
@NP	TR = 2000 ms , TE = 35 ms	14819
@NP	TR	14819
@NP	= 2000 ms , TE = 35 ms	14821
@NP	2000 ms , TE	14822
@NP	2000 ms	14822
@NP	TE	14831
@NP	d = 3 ms	14841
@NP	d	14841
@NP	= 3 ms	14842
@NP	3	14843
@NP	D = 50 ms.	14853
@NP	D	14853
@NP	= 50 ms.	14855
@NP	50	14856
@NP	The diffusion gradient strength , G ,	14863
@NP	The diffusion gradient strength	14863
@NP	G	14896
@NP	0 to 60	14920
@NP	G cm	14928
@NP	1	14933
@NP	16 steps	14938
@NP	a maximal b value of 1.12 · 106 s cm -RRB- 2 and qmax of 766 cm -RRB-	14954
@NP	a maximal b value	14954
@NP	1.12 · 106 s cm	14975
@NP	1.12 ·	14975
@NP	106 s cm	14980
@NP	106 s	14980
@NP	cm	14986
@NP	2 and qmax	14989
@NP	2	14989
@NP	qmax	14995
@NP	766 cm	15003
@NP	1	15010
@NP	Diffusion	15013
@NP	the long axis of the spine	15066
@NP	the long axis	15066
@NP	the spine	15083
@NP	The MR images	15094
@NP	a blind mode	15126
@NP	the trauma site	15143
@NP	the center of the imaged region	15173
@NP	the center	15173
@NP	the imaged region	15187
@NP	the	15187
@NP	region	15198
@NP	The signal decay of water	15206
@NP	The signal decay	15206
@NP	water	15226
@NP	the qspace approach -LSB- 12	15251
@NP	the qspace approach	15251
@NP	12	15272
@NP	the Matlab program	15282
@NP	Histological analyses	15302
@NP	cultivation , a small segment of the NOM biopsy	15333
@NP	cultivation	15333
@NP	a small segment of the NOM biopsy	15346
@NP	a small segment	15346
@NP	the NOM biopsy	15365
@NP	histological staining	15394
@NP	fixation in 10 % formalin	15422
@NP	fixation	15422
@NP	10 % formalin	15434
@NP	pH 7.4	15450
@NP	The spinal cord area	15458
@NP	the	15491
@NP	region	15503
@NP	both the proximal and the distal normal healthy stumps	15515
@NP	the proximal	15520
@NP	the distal normal healthy stumps	15537
@NP	a whole	15584
@NP	10 % formalin for several days	15601
@NP	10 % formalin	15601
@NP	several days	15618
@NP	samples	15646
@NP	ethylenediaminetetra-acetic acid -LRB- 12.5 % -RRB-	15669
@NP	ethylenediaminetetra-acetic acid	15669
@NP	12.5 %	15703
@NP	pH 7.0 for decalcification	15713
@NP	pH 7.0	15713
@NP	decalcification	15724
@NP	The softening of the calcified bony spine	15741
@NP	The softening	15741
@NP	the calcified bony spine	15758
@NP	the	15758
@NP	bony spine	15772
@NP	the smooth release	15791
@NP	the whole region	15813
@NP	the spinal cord	15833
@NP	the tube probe of the MRI system -LRB- described previously -RRB-	15879
@NP	the tube probe	15879
@NP	the MRI system	15897
@NP	histological analysis	15940
@NP	the spinal cord	15963
@NP	seven sections of 3 -- 4 mm each , in parallel	15998
@NP	seven sections of 3	15998
@NP	seven sections	15998
@NP	3	16016
@NP	4 mm each	16018
@NP	4 mm	16018
@NP	each	16023
@NP	parallel	16032
@NP	the MRI analysis	16046
@NP	The pieces	16064
@NP	tap water	16109
@NP	The samples	16120
@NP	sequential alcohols , xylol and embedded	16151
@NP	sequential alcohols	16151
@NP	xylol	16172
@NP	embedded	16182
@NP	paraffin	16194
@NP	Sections of 5	16204
@NP	Sections	16204
@NP	5	16216
@NP	6 µm were re-hydrated and stained with Meyer 's hematoxylin-eosin	16218
@NP	6 µm	16218
@NP	Meyer 's hematoxylin-eosin	16257
@NP	Meyer 's	16257
@NP	Masson 's trichrome	16284
@NP	Masson 's	16284
@NP	Bodian silver methods -LSB- 42 -RSB-	16308
@NP	Bodian silver methods	16308
@NP	42 -RSB-	16331
@NP	Immunofluorescence Cultures	16336
@NP	4 % paraformaldehyde	16380
@NP	antibodies	16419
@NP	epitopes of Olfactory Marker Protein	16438
@NP	epitopes	16438
@NP	Olfactory Marker Protein	16450
@NP	OMP	16476
@NP	Prof.	16503
@NP	F.	16509
@NP	Margolis	16512
@NP	University of Maryland , Baltimore , MD , USA -RRB-	16522
@NP	University of Maryland	16522
@NP	University	16522
@NP	Maryland	16536
@NP	Baltimore , MD , USA	16546
@NP	microtubulin associated protein-2 -LRB- MAP-2 -RRB-	16570
@NP	microtubulin associated protein-2	16570
@NP	MAP-2	16605
@NP	Cells	16613
@NP	CY2	16655
@NP	Texas Red conjugated goat anti-mouse	16662
@NP	Texas Red	16662
@NP	goat anti-mouse	16683
@NP	rabbit IgG -LRB- Jackson , diluted 1:100 -RRB-	16702
@NP	rabbit IgG	16702
@NP	Jackson , diluted 1:100	16714
@NP	Jackson	16714
@NP	1:100	16731
@NP	The stained cultures	16739
@NP	The	16739
@NP	cultures	16751
@NP	fluorescent microscope -LRB- Olympus , NY , USA -RRB-	16781
@NP	fluorescent microscope	16781
@NP	Olympus	16805
@NP	NY	16814
@NP	USA	16818
@NP	suitable filters	16828
@NP	Magnafire SP digital camera -LRB- Optronix , Mansfield NG , UK -RRB-	16868
@NP	Magnafire SP digital camera	16868
@NP	Optronix	16897
@NP	Mansfield NG	16907
@NP	UK	16921
@NP	positive control	16930
@NP	rat neuronal cultures	16948
@NP	the same conditions	16989
@NP	Results	17011
@NP	Table 1 BBB locomotor rating scale	17019
@NP	Table 1	17019
@NP	BBB locomotor rating scale	17027
@NP	the three groups of animals , two	17057
@NP	the three groups	17057
@NP	animals , two	17077
@NP	animals	17077
@NP	two	17086
@NP	one control Fig. 1	17107
@NP	one control Fig.	17107
@NP	1	17125
@NP	A tubular scaffold containing nanofibers	17127
@NP	A tubular scaffold	17127
@NP	nanofibers	17157
@NP	Original magnification	17169
@NP	25 times Fig. 2 Preparation	17192
@NP	25 times Fig.	17192
@NP	adult human NOM and human embryonic SC cultures Fig. 3	17224
@NP	adult human NOM and human embryonic SC cultures	17224
@NP	Fig. 3	17273
@NP	adult human NOM neurons	17289
@NP	a	17314
@NP	d Sprouting	17316
@NP	nerve fibers	17331
@NP	migration of nerve cells from M-cell aggregates in NVR-N-Gel	17363
@NP	migration	17363
@NP	nerve cells from M-cell aggregates in NVR-N-Gel	17376
@NP	nerve cells	17376
@NP	M-cell aggregates in NVR-N-Gel	17393
@NP	M-cell aggregates	17393
@NP	NVR-N-Gel	17414
@NP	a -- c -- 200 times , d -- 100 times .	17425
@NP	a	17425
@NP	c -- 200 times , d -- 100 times	17427
@NP	c -- 200 times , d --	17427
@NP	c	17427
@NP	200 times , d	17429
@NP	200 times	17429
@NP	d	17440
@NP	100 times	17442
@NP	a -- d Phase contrast microscopy .	17453
@NP	a	17453
@NP	d Phase contrast microscopy	17455
@NP	Immunofluorescent staining	17484
@NP	NOM neurons	17514
@NP	antibodies	17531
@NP	MAP 2 -LRB- e -RRB- and olfactory mucosa protein -LRB- OMP -RRB-	17554
@NP	MAP 2	17554
@NP	e	17561
@NP	olfactory mucosa protein	17568
@NP	OMP	17594
@NP	f	17600
@NP	Original magnification	17604
@NP	400 times	17629
@NP	f	17640
@NP	200 times	17642
@NP	Fig. 4 Phase contrast microscopy of mature motor neuron	17667
@NP	Fig. 4	17667
@NP	Phase contrast microscopy of mature motor neuron	17674
@NP	Phase contrast microscopy	17674
@NP	mature motor neuron	17703
@NP	axons in b -LRB- arrows -RRB-	17743
@NP	axons	17743
@NP	b -LRB- arrows -RRB-	17752
@NP	b	17752
@NP	arrows	17755
@NP	long-term cultures of human embryonic spinal cord	17766
@NP	long-term cultures	17766
@NP	human embryonic spinal cord	17788
@NP	Hematoxylin	18770
@NP	eosin	18783
@NP	H&E	18790
@NP	staining	18795
@NP	dispersed neuronal perikarya -LRB- a , arrows -RRB-	18817
@NP	dispersed neuronal perikarya	18817
@NP	a , arrows	18847
@NP	a	18847
@NP	arrows	18850
@NP	Silver staining	18859
@NP	nerve fibers -- either single -LRB- b , arrows -RRB- ,	18888
@NP	nerve fibers	18888
@NP	either single -LRB- b , arrows -RRB-	18901
@NP	b , arrows	18916
@NP	b	18916
@NP	arrows	18919
@NP	parallel bundles -LRB- d , arrows -RRB-	18944
@NP	parallel bundles	18944
@NP	d , arrows	18962
@NP	d	18962
@NP	arrows	18965
@NP	addition	18977
@NP	note areas of neurokeratin -LRB- c , arrows -RRB-	18987
@NP	note areas	18987
@NP	neurokeratin -LRB- c , arrows -RRB-	19001
@NP	neurokeratin	19001
@NP	c , arrows	19015
@NP	c	19015
@NP	arrows	19018
@NP	Original magnification	19027
@NP	400 times	19050
@NP	adult human NOM cells	19066
@NP	NVR-N-Gel	19112
@NP	primary stationary cultures , growth of morphologically different cell types	19125
@NP	primary stationary cultures	19125
@NP	growth of morphologically different cell types	19154
@NP	growth	19154
@NP	morphologically different cell types	19164
@NP	epithelial cells	19215
@NP	large laminae and tapered cells	19245
@NP	large laminae	19245
@NP	tapered cells	19263
@NP	islands of confluent cells	19285
@NP	islands	19285
@NP	confluent cells	19296
@NP	rise	19320
@NP	large numbers of round , unattached floating cell masses	19328
@NP	large numbers	19328
@NP	round , unattached floating cell masses	19345
@NP	round	19345
@NP	unattached floating cell masses	19352
@NP	A large number of neuronal cells	19385
@NP	A large number	19385
@NP	neuronal cells	19403
@NP	the epithelial laminae and the tapered cells	19438
@NP	the epithelial laminae	19438
@NP	the tapered cells	19465
@NP	the cultures	19486
@NP	NVR-N-Gel	19521
@NP	a growth period of 1	19542
@NP	a growth period	19542
@NP	1	19561
@NP	2 weeks in suspension on positively charged MCs	19563
@NP	2 weeks	19563
@NP	suspension on positively charged MCs	19574
@NP	suspension	19574
@NP	positively charged MCs	19588
@NP	Fig. 4	19612
@NP	Post-operative observation Seven animals out of eight in the control group	19621
@NP	Post-operative observation	19621
@NP	Seven animals	19648
@NP	eight in the control group	19669
@NP	eight	19669
@NP	the control group	19678
@NP	complete paraplegic characteristics	19706
@NP	physical examination	19745
@NP	their gait performance analysis	19773
@NP	BBB	19806
@NP	= 0 : no observable hind limb movement	19809
@NP	= 0	19809
@NP	no observable hind limb movement	19813
@NP	One rat of the control group	19848
@NP	One rat	19848
@NP	the control group	19859
@NP	slight movement of the hip joints -LRB- BBB = 1 -RRB- -LRB- Table 1 -RRB-	19884
@NP	slight movement	19884
@NP	the hip joints -LRB- BBB = 1 -RRB- -LRB- Table 1 -RRB-	19903
@NP	the hip joints -LRB- BBB = 1 -RRB-	19903
@NP	the hip joints	19903
@NP	BBB = 1	19919
@NP	Table 1	19927
@NP	Three	19937
@NP	the eight rats	19946
@NP	the group treated by a composite implant containing cultured human NOM	19964
@NP	the group	19964
@NP	a composite	19985
@NP	human NOM	20025
@NP	varying degrees of active movements	20042
@NP	varying degrees	20042
@NP	active movements	20061
@NP	One of the three rats	20079
@NP	One	20079
@NP	the three rats	20086
@NP	BBB = 3 -LRB- extensive movement of hip and knee joints -RRB-	20108
@NP	BBB	20108
@NP	3	20112
@NP	extensive movement of hip and knee joints	20115
@NP	extensive movement	20115
@NP	hip and knee joints	20137
@NP	one rat	20159
@NP	BBB	20174
@NP	10	20178
@NP	occasional weight-supported plantar steps ; no FL -- HL coordination	20182
@NP	occasional weight-supported plantar steps	20182
@NP	no FL -- HL coordination	20225
@NP	no FL	20225
@NP	HL coordination	20231
@NP	one rat	20252
@NP	BBB	20267
@NP	= 13	20270
@NP	frequent consistent weight-supported plantar steps and FL -- HL coordination	20275
@NP	frequent consistent weight-supported plantar steps	20275
@NP	FL -- HL coordination	20330
@NP	FL	20330
@NP	HL coordination	20333
@NP	Table 1	20351
@NP	Statistical analyses of the three groups of animals	20858
@NP	Statistical analyses	20858
@NP	the three groups of animals	20882
@NP	the three groups	20882
@NP	animals	20902
@NP	the BBB scale	20920
@NP	The BBB scale	20934
@NP	a normal distribution	20964
@NP	Shapiro-Wilk highly significant for two out of three groups	20987
@NP	Shapiro-Wilk highly significant for two out	20987
@NP	Shapiro-Wilk	20987
@NP	two	21023
@NP	three groups	21034
@NP	A non-parametric test	21049
@NP	the groups	21100
@NP	The Kruskal	21112
@NP	Wallis test	21124
@NP	a significant difference between the groups -LRB- p = 0.0117 -RRB-	21142
@NP	a significant difference	21142
@NP	the groups -LRB- p = 0.0117 -RRB-	21175
@NP	the groups	21175
@NP	p	21187
@NP	0.0117	21189
@NP	the group pairs	21215
@NP	we	21259
@NP	the Duncan multiple comparison test	21267
@NP	the ranked data -LRB- as the raw data is non-normal -RRB-	21306
@NP	the ranked data	21306
@NP	the raw data	21326
@NP	The mean rank of human embryonic spinal cord group -LRB- 16.88 -RRB-	21355
@NP	The mean rank of human embryonic spinal cord group	21355
@NP	The mean rank	21355
@NP	human embryonic spinal cord group	21372
@NP	16.88	21407
@NP	both the human NOM and control groups	21443
@NP	the human NOM	21448
@NP	control groups	21466
@NP	means of 10.5 and 7.31 , respectively	21482
@NP	means of 10.5 and 7.31	21482
@NP	means	21482
@NP	10.5 and 7.31	21491
@NP	No significant difference	21521
@NP	the NOM and control groups	21570
@NP	the NOM	21570
@NP	control groups	21582
@NP	Electrophysiological measurements	21598
@NP	Spinal cord conductivities	21632
@NP	spinal cord transection	21691
@NP	3 months	21725
@NP	two groups	21743
@NP	transection alone , or transection plus implantation of composite NOMimplants	21754
@NP	transection alone , or transection	21754
@NP	transection alone	21754
@NP	transection	21776
@NP	implantation of composite NOMimplants	21793
@NP	implantation	21793
@NP	composite NOMimplants	21809
@NP	two out of the three NOM implanted-rats exhibiting legs movements	21835
@NP	two	21835
@NP	the three NOM implanted-rats	21846
@NP	legs movements	21886
@NP	SSEPs	21902
@NP	Fig. 6b	21923
@NP	No SSEP response	21933
@NP	the eight rats of the control group	21966
@NP	the eight rats	21966
@NP	the control group	21984
@NP	the five rats of the NOM	22010
@NP	the five rats	22010
@NP	the NOM	22027
@NP	group that did not show leg movement -LRB- Fig. 6a -RRB-	22045
@NP	group	22045
@NP	leg movement -LRB- Fig. 6a -RRB-	22069
@NP	leg movement	22069
@NP	Fig. 6a	22083
@NP	MRI analysis Representatives of the treatment groups	22093
@NP	MRI analysis Representatives	22093
@NP	the treatment groups	22125
@NP	MRI analysis	22164
@NP	information	22193
@NP	the state of the spinal cord tissue	22208
@NP	the state	22208
@NP	the spinal cord tissue	22221
@NP	the injury site	22247
@NP	Magnetic resonance -LRB- MR -RRB- q-space displacement	22264
@NP	Magnetic resonance -LRB- MR -RRB-	22264
@NP	Magnetic resonance	22264
@NP	MR	22284
@NP	-LSB- 1 , 2 -RSB- , which were computed for three different spinal cords ,	22314
@NP	-LSB- 1 , 2 -RSB-	22314
@NP	three different spinal cords	22346
@NP	fiber-like tissue with an amount of water-restricted diffusion	22390
@NP	fiber-like tissue	22390
@NP	an amount of water-restricted diffusion	22413
@NP	an amount	22413
@NP	water-restricted diffusion	22426
@NP	the treated spinal cords	22473
@NP	the controls -LRB- Fig. 7 -RRB-	22509
@NP	the controls	22509
@NP	Fig. 7	22523
@NP	comparison of slices numbers 3 -- 5 , which are of the implantation sites ,	22542
@NP	comparison	22542
@NP	slices numbers 3 -- 5	22556
@NP	slices numbers	22556
@NP	3 -- 5	22571
@NP	the implantation sites	22589
@NP	small areas	22618
@NP	the mean displacement	22639
@NP	less than 4 µm -LRB- value consistent with normal white matter -RRB-	22664
@NP	less than 4 µm	22664
@NP	value	22680
@NP	normal white matter	22702
@NP	Such areas	22724
@NP	slices of implanted rats	22755
@NP	slices	22755
@NP	implanted rats	22765
@NP	the controls -LRB- Fig. 7 -RRB-	22792
@NP	the controls	22792
@NP	Fig. 7	22806
@NP	Histological analysis	22815
@NP	The dominant histological picture	22837
@NP	the reparative tissue in the area of the excised cord tissue	22874
@NP	the reparative tissue	22874
@NP	the area of the excised cord tissue	22899
@NP	the area	22899
@NP	the excised cord tissue	22911
@NP	the	22911
@NP	cord tissue	22923
@NP	the presence of fibrotic scar tissue	22939
@NP	the presence	22939
@NP	fibrotic scar tissue	22955
@NP	glial cells and fibroblasts	22989
@NP	the formation of new blood vessels	23032
@NP	the formation	23032
@NP	new blood vessels	23049
@NP	No inflammatory reaction	23068
@NP	the histology of rats implanted with human cells or in the control rats	23116
@NP	the histology	23116
@NP	rats implanted with human cells or in the control rats	23133
@NP	rats	23133
@NP	human cells	23153
@NP	the control rats	23171
@NP	rats implanted with either human NOM or with embryonic spinal cord	23192
@NP	rats	23192
@NP	human NOM	23219
@NP	embryonic spinal cord	23237
@NP	the H&E	23259
@NP	sections	23275
@NP	some areas	23291
@NP	neurokeratin	23305
@NP	axons	23326
@NP	an empty space	23346
@NP	residual of the myelin sheath that had been dissolved by the alcohol treatment	23362
@NP	residual	23362
@NP	the myelin sheath	23374
@NP	the alcohol treatment	23419
@NP	one rat	23459
@NP	the right leg	23488
@NP	NOM implantation	23508
@NP	a number of large neuronal perikarya	23526
@NP	a number	23526
@NP	large neuronal perikarya	23538
@NP	the implanted area -LRB- Fig. 8a , c -RRB-	23580
@NP	the implanted area	23580
@NP	Fig. 8a , c	23600
@NP	Fig. 8a	23600
@NP	c	23609
@NP	silver stained sections of both composite implants	23616
@NP	silver	23616
@NP	sections of both composite implants	23631
@NP	sections	23631
@NP	both composite implants	23643
@NP	Discussion Regeneration and repair	23668
@NP	complete transection injuries of the spinal cord	23706
@NP	complete transection injuries	23706
@NP	the spinal cord	23739
@NP	an unresolved clinical challenge	23764
@NP	Various experimental approaches	23798
@NP	reconstructive regeneration and renewal of damaged spinal cord	23834
@NP	reconstructive regeneration and renewal	23834
@NP	damaged spinal cord	23877
@NP	intensive investigation in laboratory animals	23907
@NP	intensive investigation	23907
@NP	laboratory animals	23934
@NP	The strategies	23954
@NP	stimulation of positive autoimmune responses -LSB- 16	23977
@NP	stimulation	23977
@NP	positive autoimmune responses -LSB- 16	23992
@NP	positive autoimmune responses	23992
@NP	16	24023
@NP	50 -RSB-	24027
@NP	introduction of neurotrophic and neuroprotective agents	24032
@NP	introduction	24032
@NP	neurotrophic and neuroprotective agents	24048
@NP	-LSB- 8 , 14 , 22 , 23 , 34 , 36 -RSB-	24088
@NP	removal and elimination of scar inhibitory molecules	24116
@NP	removal and elimination	24116
@NP	scar inhibitory molecules	24143
@NP	-LSB- 11 , 21 , 24 , 30 , 53 -RSB-	24169
@NP	The latest technologies for solving paraplegic conditions	24191
@NP	The latest technologies	24191
@NP	paraplegic conditions	24227
@NP	several kinds	24256
@NP	cell therapy	24273
@NP	the damaged site of the spinal cord	24311
@NP	the damaged site	24311
@NP	the spinal cord	24331
@NP	removal	24353
@NP	the accumulated scar -LSB- 47 -RSB-	24364
@NP	the accumulated scar	24364
@NP	47 -RSB-	24386
@NP	-LRB- a -RRB- Implantation of tissue-engineered devices	24391
@NP	Implantation	24395
@NP	tissue-engineered devices	24411
@NP	cells	24446
@NP	anchorage of the implant and for guiding axonal regeneration -LSB- 59 , 60 -RSB-	24457
@NP	anchorage	24457
@NP	the implant and for guiding axonal regeneration -LSB- 59 , 60 -RSB-	24470
@NP	guiding axonal regeneration -LSB- 59 , 60	24490
@NP	guiding axonal regeneration	24490
@NP	-LSB- 59 , 60	24518
@NP	Composite implants	24532
@NP	cells of either autologous or allogeneic origin -LSB- 18 , 35 , 37 , 41	24563
@NP	cells	24563
@NP	either autologous or allogeneic origin -LSB- 18 , 35 , 37 , 41	24572
@NP	either autologous or allogeneic origin	24572
@NP	-LSB- 18 , 35 , 37 , 41	24611
@NP	The choice of cell resources	24629
@NP	The choice	24629
@NP	cell resources	24643
@NP	stem cells	24690
@NP	mature neurogenic phenotypes	24734
@NP	insertion of already mature neuronal committed cells	24766
@NP	insertion	24766
@NP	already mature neuronal committed cells	24779
@NP	the current project	24823
@NP	both cell sources of the composite implants	24844
@NP	both cell sources	24844
@NP	the composite implants	24865
@NP	human origin	24895
@NP	the rat spinal cord system	24920
@NP	xenogeneic cell implants	24950
@NP	they	24976
@NP	future clinical studies	24994
@NP	NOM cells	25042
@NP	embryonic spinal cord cells	25069
@NP	embryonic spinal cord	25069
@NP	cells	25091
@NP	The innovative cell culture techniques described in the Methods section	25121
@NP	The innovative cell culture techniques	25121
@NP	the Methods section	25173
@NP	the purpose	25200
@NP	high concentrations of neural cell cultures ideally -LSB- 19 , 51 -RSB-	25228
@NP	high concentrations	25228
@NP	neural cell cultures ideally -LSB- 19 , 51 -RSB-	25251
@NP	neural cell cultures	25251
@NP	-LSB- 19 , 51 -RSB-	25280
@NP	These cells	25290
@NP	a milieu of a gel enriched with adhesive molecules -LSB- 13 , 38	25318
@NP	a milieu	25318
@NP	a gel enriched with adhesive molecules -LSB- 13 , 38	25330
@NP	a gel	25330
@NP	adhesive molecules	25350
@NP	-LSB- 13 , 38	25369
@NP	neurotrophic and neuroprotective agents	25382
@NP	antioxidants , which are released slowly	25425
@NP	antioxidants	25425
@NP	addition	25469
@NP	the gel	25479
@NP	the nanofilaments in the tubular scaffold	25494
@NP	the nanofilaments	25494
@NP	the tubular scaffold	25515
@NP	The gel and the scaffold	25537
@NP	The gel	25537
@NP	the scaffold	25549
@NP	Other reports in the literature	25613
@NP	Other reports	25613
@NP	the literature	25630
@NP	auxiliary tissue	25654
@NP	engineered products	25672
@NP	neuronal and axonal growth	25705
@NP	nanofibrils	25741
@NP	52	25754
@NP	59	25758
@NP	60 -RSB-	25762
@NP	gels	25767
@NP	34	25773
@NP	56	25777
@NP	57 -RSB-	25781
@NP	scaffolds	25789
@NP	-LSB- 22 , 54 , 55 -RSB-	25799
@NP	Acellular devices yiel	25813
@NP	poorer and limited results in comparison	25841
@NP	poorer and limited results	25841
@NP	comparison	25871
@NP	cellcontaining implants -LSB- 47 -RSB-	25885
@NP	cellcontaining implants	25885
@NP	47 -RSB-	25910
@NP	A variety of sources for implantation	25915
@NP	A variety	25915
@NP	sources for implantation	25928
@NP	sources	25928
@NP	implantation	25940
@NP	bone marrow stroma cells	25981
@NP	25	26007
@NP	33	26011
@NP	58 -RSB-	26015
@NP	skin	26020
@NP	umbilical cord blood	26026
@NP	embryonal and fetal stem cell lines	26051
@NP	-LSB- 20 , 37 , 41 , 43 , 61 -RSB-	26087
@NP	those cell sources	26118
@NP	only sporadic appearances of single cells or cell aggregates of neuronal cells	26160
@NP	only sporadic appearances	26160
@NP	single cells or cell aggregates of neuronal cells	26189
@NP	single cells or cell aggregates	26189
@NP	neuronal cells	26224
@NP	robust numbers of neuronal cells	26260
@NP	robust numbers	26260
@NP	neuronal cells	26278
@NP	a successful	26303
@NP	massive segmental losses	26341
@NP	the current study	26370
@NP	embryonic spinal cord and adult NOM cells	26389
@NP	vigorous vitality	26438
@NP	rich neurogenic cell cultures	26473
@NP	implantation	26507
@NP	Both types of xenogeneic implants	26521
@NP	Both types	26521
@NP	xenogeneic implants	26535
@NP	the current study bear	26563
@NP	the risk of inducing an immunogenic response	26586
@NP	the risk	26586
@NP	an immunogenic response	26607
@NP	the results	26655
@NP	neither of them	26677
@NP	neither	26677
@NP	them	26688
@NP	a rejection response	26700
@NP	the other hand	26725
@NP	preliminary results of studies currently in progress	26741
@NP	preliminary results	26741
@NP	studies currently in progress	26764
@NP	studies	26764
@NP	progress	26785
@NP	NOM cells of adult dogs	26818
@NP	NOM cells	26818
@NP	adult dogs	26831
@NP	paralytic rats	26862
@NP	severe rejection	26878
@NP	the death of animals	26902
@NP	the death	26902
@NP	animals	26915
@NP	a few days	26923
@NP	the implantation	26940
@NP	It	26958
@NP	the spinal cord and its surrounding fluids	26987
@NP	the spinal cord	26987
@NP	its surrounding fluids	27007
@NP	an immunologically privileged site	27045
@NP	minimal immunologic responses	27086
@NP	The human embryonal spinal cord implants in our study	27117
@NP	The human embryonal spinal cord implants	27117
@NP	our study	27161
@NP	significant advantages	27178
@NP	the control animals	27206
@NP	repair of the tissue damage	27236
@NP	repair	27236
@NP	the tissue damage	27246
@NP	no means	27271
@NP	The rats implanted with the adult human NOM cells	27290
@NP	The rats	27290
@NP	the adult human NOM cells	27314
@NP	statistically insignificant advantages	27347
@NP	the control group of animals	27391
@NP	the control group	27391
@NP	animals	27412
@NP	the course of further experiments being performed	27424
@NP	the course	27424
@NP	further experiments being performed	27438
@NP	further experiments	27438
@NP	we	27475
@NP	more insight	27490
@NP	the growth of the human adult NOM biopsy	27508
@NP	the growth	27508
@NP	the human adult NOM biopsy	27522
@NP	further selecting	27553
@NP	specific sub-populations of cells	27590
@NP	specific sub-populations	27590
@NP	cells	27618
@NP	the overall collected mixture	27629
@NP	the overall	27629
@NP	mixture	27651
@NP	The outcome of these experiments	27660
@NP	The outcome	27660
@NP	these experiments	27675
@NP	the contribution of the different adult human NOM cell-populations	27713
@NP	the contribution	27713
@NP	the different adult human NOM cell-populations	27733
@NP	the recent years	27786
@NP	MRI	27803
@NP	the most important imaging modality	27826
@NP	the central nervous system -LRB- CNS -RRB-	27866
@NP	the central nervous system	27866
@NP	CNS	27894
@NP	Water diffusion	27900
@NP	an important contrast mechanism in MRI of the CNS	27919
@NP	an important contrast mechanism	27919
@NP	MRI of the CNS	27954
@NP	MRI	27954
@NP	the CNS	27961
@NP	diffusion weighted imaging -LRB- DWI -RRB-	27970
@NP	diffusion weighted imaging	27970
@NP	DWI	27998
@NP	diffusion tensor imagings -LRB- DTI -RRB-	28007
@NP	diffusion tensor imagings	28007
@NP	DTI	28034
@NP	CNS pathologies and structures	28073
@NP	-LSB- 31 , 32 -RSB-	28104
@NP	The DTI	28114
@NP	fiber orientations	28154
@NP	31 -RSB-	28174
@NP	we	28189
@NP	high b-value q-space diffusion MRI	28215
@NP	the structural	28276
@NP	the pathophysiological state	28295
@NP	axons and fibers of the CNS	28327
@NP	axons and fibers	28327
@NP	the CNS	28347
@NP	1 -- 3 , 10 -RSB- ,	28356
@NP	1 -- 3	28356
@NP	10 -RSB-	28361
@NP	CNS maturation and degeneration -LSB- 3 -RSB-	28396
@NP	CNS maturation and degeneration	28396
@NP	3 -RSB-	28429
@NP	the current study	28451
@NP	the first two rats transplanted with cell-containing composite implants	28469
@NP	the first two rats	28469
@NP	cell-containing composite implants	28506
@NP	some regeneration	28548
@NP	motor function and axons	28569
@NP	the electrophysiological measurements	28611
@NP	MRI	28650
@NP	some histological evidence of formation of cells and axonal fibers	28659
@NP	some histological evidence	28659
@NP	formation of cells and axonal fibers	28689
@NP	formation	28689
@NP	cells and axonal fibers	28702
@NP	cells	28702
@NP	axonal fibers	28712
@NP	It	28727
@NP	more MRI experiments	28744
@NP	these preliminary results	28789
@NP	axonal connection	28826
@NP	the transplanted zone	28874
@NP	Such MRI experiments	28897
@NP	underway	28922
@NP	The MRI analyses	28932
@NP	both the electrophysiological tests and the histological findings	28966
@NP	the electrophysiological tests	28971
@NP	the histological findings	29006
@NP	neuronal cells	29035
@NP	axons	29063
@NP	sections	29075
@NP	the composite	29087
@NP	transplants , versus their absence	29111
@NP	transplants	29111
@NP	their absence	29131
@NP	the sections of the control animals	29148
@NP	the sections	29148
@NP	the control animals	29164
@NP	summary	29188
@NP	the current study	29200
@NP	we	29218
@NP	the combined efforts of cell cultivation , differentiation and integration	29230
@NP	the combined efforts	29230
@NP	cell cultivation , differentiation and integration	29254
@NP	cell cultivation	29254
@NP	differentiation	29272
@NP	integration	29292
@NP	a tissue-engineered scaffold	29309
@NP	a composite	29342
@NP	spinal cord injury	29376
@NP	Reliable tests to evaluate the final outcomes of the spinal cord injured regions	29396
@NP	the final outcomes of the spinal cord injured regions	29423
@NP	the final outcomes	29423
@NP	the spinal cord injured regions	29445
@NP	the spinal cord	29445
@NP	regions	29469
@NP	results that brought us closer to the goal of treatment of damaged spinal cord	29485
@NP	results	29485
@NP	us	29506
@NP	the goal of treatment of damaged spinal cord	29519
@NP	the goal	29519
@NP	treatment of damaged spinal cord	29531
@NP	treatment	29531
@NP	damaged spinal cord	29544
@NP	we	29579
@NP	the problem of elimination of scar tissue , which still needs to be addressed	29595
@NP	the problem	29595
@NP	elimination of scar tissue , which still needs to be addressed	29610
@NP	elimination	29610
@NP	scar tissue , which still needs to be addressed	29625
@NP	scar tissue	29625
@NP	These results	29673
@NP	we	29708
@NP	still a long way	29716
@NP	complete motor function and full gait performance	29746
@NP	complete motor function	29746
@NP	full gait performance	29774
@VP	was designed to assess a new composite	117
@VP	designed to assess a new composite	121
@VP	to assess a new composite	130
@VP	assess a new composite	133
@VP	containing bundles of parallel nanofibers	593
@VP	was developed	636
@VP	developed	640
@VP	were made of a biodegradable dextran sulphate -- gelatin co-precipitate	684
@VP	made of a biodegradable dextran sulphate -- gelatin co-precipitate	689
@VP	implant at the site of injury and provided guidance for the regenerating axons	790
@VP	implant at the site of injury	790
@VP	provided guidance for the regenerating axons	824
@VP	had been completely removed	981
@VP	been completely removed	985
@VP	had also been transected	1047
@VP	been transected	1056
@VP	transected	1061
@VP	implanted with a composite implant of cultured human embryonic spinal cord cells	1077
@VP	implant of cultured human embryonic spinal cord cells	1104
@VP	cultured human embryonic spinal cord cells	1115
@VP	served as a control group	1192
@VP	performed 3 months after implantation	1258
@VP	were implanted with cultured human embryonic spinal cord cells	1442
@VP	implanted with cultured human embryonic spinal cord cells	1447
@VP	cultured human embryonic spinal cord cells	1462
@VP	remained completely paralyzed	1535
@VP	did not show transmission of stimuli to the brain	1569
@VP	show transmission of stimuli to the brain	1577
@VP	implant to bridge a gap resulting from the transection and removal of a 4 mm	1663
@VP	to bridge a gap resulting from the transection and removal of a 4 mm	1671
@VP	bridge a gap resulting from the transection and removal of a 4 mm	1674
@VP	resulting from the transection and removal of a 4 mm	1687
@VP	may serve as a vital bridging station in acute and chronic cases of paraplegia	1886
@VP	serve as a vital bridging station in acute and chronic cases of paraplegia	1890
@VP	involving partial or complete transection	2001
@VP	are unable to heal on their own	2097
@VP	to heal on their own	2108
@VP	heal on their own	2111
@VP	cause loss of sensory , motor and , reflex functions below the site of injury	2188
@VP	have been used in attempting to reconstruct an injured spinal cord	2294
@VP	been used in attempting to reconstruct an injured spinal cord	2299
@VP	used in attempting to reconstruct an injured spinal cord	2304
@VP	attempting to reconstruct an injured spinal cord	2312
@VP	to reconstruct an injured spinal cord	2323
@VP	reconstruct an injured spinal cord	2326
@VP	introducing growth factor-treated implants -LSB- 22 , 23 , 39 -RSB-	2442
@VP	have been attempted with limited success	2540
@VP	been attempted with limited success	2545
@VP	attempted with limited success	2550
@VP	using implantation of cells from various sources	2711
@VP	has been gaining momentum in recent years -LSB- 28 , 41 -RSB-	2760
@VP	been gaining momentum in recent years -LSB- 28 , 41 -RSB-	2764
@VP	gaining momentum in recent years -LSB- 28 , 41 -RSB-	2769
@VP	tend to desert the injury site	2966
@VP	to desert the injury site	2971
@VP	desert the injury site	2974
@VP	repairing injured mammalian spinal cord	3029
@VP	creating a composite implant	3075
@VP	implant	3096
@VP	contains cultured cells from an autologous or allogeneic source	3111
@VP	cultured cells from an autologous or allogeneic source	3120
@VP	to connect the stumps of the severed spinal cords -LSB- 44 -RSB-	3229
@VP	connect the stumps of the severed spinal cords -LSB- 44 -RSB-	3232
@VP	implant	3314
@VP	includes	3322
@VP	to anchor the implanted cells	3440
@VP	anchor the implanted cells	3443
@VP	are embedded in a viscous adhesive milieu	3477
@VP	embedded in a viscous adhesive milieu	3481
@VP	supplemented with a variety of factors -LSB- 47 -RSB-	3520
@VP	is now a step closer to reality -LSB- 27 , 37 -RSB-	3675
@VP	using such human embryonic stem cells	3956
@VP	would be considered as an allogeneic graft	3994
@VP	be considered as an allogeneic graft	4000
@VP	considered as an allogeneic graft	4003
@VP	is the nasal olfactory mucosa -LRB- NOM -RRB-	4208
@VP	is easily biopsied	4260
@VP	biopsied	4270
@VP	receiving and transmitting signals as a '' relay station '' in the spinal cord	4524
@VP	produced by tissue-engineering technologies for spinal cord implantation	4616
@VP	are categorized into synthetic and naturally occurring polymeric macromolecules	4689
@VP	categorized into synthetic and naturally occurring polymeric macromolecules	4693
@VP	are commonly grouped into protein-peptides-based scaffolds and carbohydrates	4799
@VP	grouped into protein-peptides-based scaffolds and carbohydrates	4812
@VP	based scaffolds -LSB- 26 , 29 , 52 -RSB-	4877
@VP	matches the ECM constituents of many tissues , including that of the spinal cord	5105
@VP	supporting the vitality of the neuronal bridge	5532
@VP	have the consistency of colloidal-gels	5625
@VP	have been proposed for repairing injured spinal cord -LSB- 34 , 56 , 57 -RSB-	5699
@VP	been proposed for repairing injured spinal cord -LSB- 34 , 56 , 57 -RSB-	5704
@VP	proposed for repairing injured spinal cord -LSB- 34 , 56 , 57 -RSB-	5709
@VP	repairing injured spinal cord -LSB- 34 , 56 , 57 -RSB-	5722
@VP	consisting of two	6088
@VP	naturally occurring biological cross-linked polymers	6106
@VP	made of the same material as the scaffold -LRB- Fig. 1 -RRB-	6350
@VP	be biocompatible , non-toxic , and non-inflammatory -LRB- data not shown -RRB-	6467
@VP	not shown	6523
@VP	is transparent , suturable	6544
@VP	takes place -LRB- data not shown -RRB-	6643
@VP	not shown	6661
@VP	is a proprietary product of NVR Labs -LRB- patent pending -RRB-	6690
@VP	crosslinked hyaluronic acid with the adhesive molecule laminin	6762
@VP	is transparent	7098
@VP	highly hydrated with polar and non-polar -LRB- hydrophobic -RRB- residues	7114
@VP	is used at a concentration of 0.7 -- 1 % hyaluronic acid , however	7246
@VP	used at a concentration of 0.7 -- 1 % hyaluronic acid , however	7249
@VP	is used	7355
@VP	used	7358
@VP	were collected for cell isolation and the establishment of cultures	7547
@VP	collected for cell isolation and the establishment of cultures	7552
@VP	was obtained from each patient	7754
@VP	obtained from each patient	7758
@VP	was introduced as outlined in the scheme -LRB- Fig. 2 -RRB-	7818
@VP	introduced as outlined in the scheme -LRB- Fig. 2 -RRB-	7822
@VP	outlined in the scheme -LRB- Fig. 2 -RRB-	7836
@VP	equilibrated with phosphate buffered saline -LRB- PBS -RRB- pH 7.4	8081
@VP	autoclaved in batches of 15 g in 100 ml PBS -LSB- 19 , 51 -RSB-	8142
@VP	dissociated cells	8200
@VP	were grown in suspension attached to the MCs for periods of 1 -- 4 weeks	8218
@VP	grown in suspension attached to the MCs for periods of 1 -- 4 weeks	8223
@VP	attached to the MCs for periods of 1 -- 4 weeks	8243
@VP	were collected and reseeded in NVR-N-Gel as stationary cultures	8367
@VP	collected and reseeded in NVR-N-Gel as stationary cultures	8372
@VP	is omitted	8789
@VP	omitted	8792
@VP	are added	8889
@VP	added	8893
@VP	were supplemented with the same factors used to enrich the gel	8911
@VP	supplemented with the same factors used to enrich the gel	8916
@VP	used to enrich the gel	8951
@VP	to enrich the gel	8956
@VP	enrich the gel	8959
@VP	were enriched with 10 % fetal calf serum -LRB- FCS -RRB-	9005
@VP	enriched with 10 % fetal calf serum -LRB- FCS -RRB-	9010
@VP	was omitted from the media	9106
@VP	omitted from the media	9110
@VP	were usually cultured for 3 -- 4 weeks prior to implantation	9140
@VP	cultured for 3 -- 4 weeks prior to implantation	9153
@VP	authorized by the local ethical committee for experiments in laboratory animals	9252
@VP	weighing approximately 250 g	9731
@VP	were used	9761
@VP	used	9766
@VP	were anesthetized by intraperitoneal injections	9781
@VP	was used : 50 mg/kg Ketamine and 1.8 mg/kg Xylosine	10126
@VP	was used	10126
@VP	used	10130
@VP	follow up tests were performed in a double blind randomized manner	10205
@VP	were performed in a double blind randomized manner	10221
@VP	performed in a double blind randomized manner	10226
@VP	was exposed via a dorsal approach	10449
@VP	exposed via a dorsal approach	10453
@VP	were retracted	10506
@VP	retracted	10511
@VP	removed	10536
@VP	was completely transected using micro-scissors	10561
@VP	transected using micro-scissors	10576
@VP	using micro-scissors	10587
@VP	was removed	10639
@VP	removed	10643
@VP	formed after removal of the scar in chronic spinal cord injuries	10696
@VP	underwent spinal cord transection and the removal of a 4 mm spinal cord segment	10787
@VP	were closed with no further treatment -LRB- sham treated control group -RRB-	10868
@VP	closed with no further treatment -LRB- sham treated control group -RRB-	10873
@VP	treated control group	10912
@VP	underwent implantation of one of the composite implants	10958
@VP	were treated with implants containing NOM cells -LRB- Fig. 3 -RRB- and four rats	11026
@VP	treated with implants containing NOM cells -LRB- Fig. 3 -RRB- and four rats	11031
@VP	containing NOM cells -LRB- Fig. 3 -RRB- and four rats	11053
@VP	received human embryonal spinal cord-derived cells	11097
@VP	grown as long term cultures to the stage of myelin formation -LRB- Fig. 4 -RRB-	11188
@VP	embedded in NVR-N-Gel , and encapsulated in NVR scaffold	11301
@VP	embedded in NVR-N-Gel	11301
@VP	encapsulated in NVR scaffold	11328
@VP	were implanted into the site of the excised spinal cord segment	11358
@VP	implanted into the site of the excised spinal cord segment	11363
@VP	excised spinal cord segment	11394
@VP	containing the implant	11602
@VP	implant	11617
@VP	were closed and sutured	11843
@VP	closed and sutured	11848
@VP	was taken to minimize discomfort and pain	11955
@VP	taken to minimize discomfort and pain	11959
@VP	to minimize discomfort and pain	11965
@VP	minimize discomfort and pain	11968
@VP	maintained in ventilated cages , containing sterile sawdust and sterile food	12131
@VP	containing sterile sawdust and sterile food	12163
@VP	were kept solitary in cages	12228
@VP	kept solitary in cages	12233
@VP	were gathered in groups for 1 h every day , in a large facility	12261
@VP	gathered in groups for 1 h every day , in a large facility	12266
@VP	were sacrificed under general anesthesia	12376
@VP	sacrificed under general anesthesia	12381
@VP	evoked potentials	12466
@VP	placed on the rats ' scalps	12765
@VP	was placed on the thigh , on the side of the stimulation	12979
@VP	placed on the thigh , on the side of the stimulation	12983
@VP	was stimulated by a bipolar stimulating electrode	13054
@VP	stimulated by a bipolar stimulating electrode	13058
@VP	were generated at a rate of 3 s -RRB- 1	13172
@VP	generated at a rate of 3 s -RRB- 1	13177
@VP	was increased gradually , until slight twitching of the limb appeared	13230
@VP	increased gradually , until slight twitching of the limb appeared	13234
@VP	appeared	13290
@VP	evoked potentials , as a response to stimulation in two consecutive tests	13318
@VP	was considered positive	13392
@VP	considered positive	13396
@VP	were measured The rats	13462
@VP	measured The rats	13467
@VP	were anesthetized intra-operatively with diluted Nembutal	13485
@VP	-LSB- 5 -RSB-	13781
@VP	were excised and fixed with formalin	14103
@VP	excised and fixed with formalin	14108
@VP	immersed in Fluorinert -LRB- Sigma Chemical Co. , St.	14277
@VP	was maintained at 25.0 ± 0.1 C for the duration of the experiments	14372
@VP	maintained at 25.0 ± 0.1 C for the duration of the experiments	14376
@VP	producing pulse gradients	14606
@VP	giving a maximal b value of 1.12 · 106 s cm -RRB- 2 and qmax of 766 cm -RRB- 1	14947
@VP	was measured perpendicular and parallel to the long axis of the spine	15023
@VP	measured perpendicular and parallel to the long axis of the spine	15027
@VP	were collected in a blind mode	15108
@VP	collected in a blind mode	15113
@VP	was placed at the center of the imaged region	15159
@VP	placed at the center of the imaged region	15163
@VP	imaged region	15191
@VP	was analyzed using the qspace approach -LSB- 12 -RSB- using the Matlab program	15232
@VP	analyzed using the qspace approach -LSB- 12 -RSB- using the Matlab program	15236
@VP	using the qspace approach -LSB- 12 -RSB- using the Matlab program	15245
@VP	using the qspace approach -LSB- 12	15245
@VP	using the Matlab program	15276
@VP	was taken for histological staining after fixation in 10 % formalin at pH 7.4	15380
@VP	taken for histological staining after fixation in 10 % formalin at pH 7.4	15384
@VP	implant region with both the proximal and the distal normal healthy stumps	15495
@VP	was fixed as a whole mount in 10 % formalin for several days	15571
@VP	fixed as a whole mount in 10 % formalin for several days	15575
@VP	mount in 10 % formalin for several days	15592
@VP	calcified bony spine	15762
@VP	inserted into the tube probe of the MRI system -LRB- described previously -RRB-	15865
@VP	described previously	15913
@VP	were rinsed thoroughly in running tap water	16075
@VP	rinsed thoroughly in running tap water	16080
@VP	running tap water	16101
@VP	were dehydrated in sequential alcohols , xylol and embedded in paraffin	16132
@VP	dehydrated in sequential alcohols , xylol and embedded in paraffin	16137
@VP	were re-hydrated and stained with Meyer 's hematoxylin-eosin	16223
@VP	re-hydrated and stained with Meyer 's hematoxylin-eosin	16228
@VP	re-hydrated	16228
@VP	stained with Meyer 's hematoxylin-eosin	16244
@VP	fixed with 4 % paraformaldehyde	16369
@VP	was kindly provided by Prof.	16480
@VP	provided by Prof.	16491
@VP	conjugated goat anti-mouse	16672
@VP	diluted 1:100	16723
@VP	stained cultures	16743
@VP	using Magnafire SP digital camera -LRB- Optronix , Mansfield NG , UK -RRB-	16862
@VP	were stained under the same conditions	16970
@VP	stained under the same conditions	16975
@VP	containing nanofibers	17146
@VP	Cultured adult human NOM neurons	17280
@VP	demonstrates dispersed neuronal perikarya -LRB- a , arrows -RRB-	18804
@VP	demonstrates nerve fibers -- either single -LRB- b , arrows -RRB- ,	18875
@VP	organized in parallel bundles -LRB- d , arrows -RRB-	18931
@VP	was observed	19201
@VP	observed	19205
@VP	forming islands of confluent cells	19277
@VP	giving rise to large numbers of round , unattached floating cell masses	19313
@VP	showed slight movement of the hip joints -LRB- BBB = 1 -RRB- -LRB- Table 1 -RRB-	19877
@VP	treated by a composite implant containing cultured human NOM	19974
@VP	implant containing cultured human NOM	19997
@VP	containing cultured human NOM	20005
@VP	cultured human NOM	20016
@VP	showed varying degrees of active movements	20035
@VP	showed BBB = 3 -LRB- extensive movement of hip and knee joints -RRB-	20101
@VP	graded by the BBB scale	20910
@VP	is therefore used to compare the groups	21071
@VP	used to compare the groups	21084
@VP	to compare the groups	21089
@VP	compare the groups	21092
@VP	shows a significant difference between the groups -LRB- p = 0.0117 -RRB-	21136
@VP	To test which of the group pairs is significantly different	21198
@VP	test which of the group pairs is significantly different	21201
@VP	is significantly different	21231
@VP	is non-normal	21339
@VP	emerged when comparing the NOM and control groups	21547
@VP	comparing the NOM and control groups	21560
@VP	out of the three NOM implanted-rats exhibiting legs movements	21839
@VP	were elicited -LRB- Fig. 6b -RRB-	21908
@VP	elicited -LRB- Fig. 6b -RRB-	21913
@VP	was elicited in the eight rats of the control group	21950
@VP	elicited in the eight rats of the control group	21954
@VP	did not show leg movement -LRB- Fig. 6a -RRB-	22056
@VP	show leg movement -LRB- Fig. 6a -RRB-	22064
@VP	provided information on the state of the spinal cord tissue at the injury site	22184
@VP	were computed for three different spinal cords	22328
@VP	computed for three different spinal cords	22333
@VP	are of the implantation sites	22582
@VP	is less than 4 µm -LRB- value consistent with normal white matter -RRB-	22661
@VP	excised cord tissue	22915
@VP	was the presence of fibrotic scar tissue	22935
@VP	implanted with human cells or in the control rats	23138
@VP	implanted with either human NOM or with embryonic spinal cord	23197
@VP	had been dissolved by the alcohol treatment	23397
@VP	been dissolved by the alcohol treatment	23401
@VP	dissolved by the alcohol treatment	23406
@VP	was walking on the right leg after NOM implantation	23473
@VP	walking on the right leg after NOM implantation	23477
@VP	were observed in the implanted area -LRB- Fig. 8a , c -RRB-	23563
@VP	observed in the implanted area -LRB- Fig. 8a , c -RRB-	23568
@VP	stained sections of both composite implants	23623
@VP	is still an unresolved clinical challenge	23755
@VP	are under intensive investigation in laboratory animals	23897
@VP	solving paraplegic conditions	24219
@VP	implant	24474
@VP	-RSB-	24626
@VP	serving in the rat spinal cord system as xenogeneic cell implants	24909
@VP	described in the Methods section	25160
@VP	enriched with adhesive molecules -LSB- 13 , 38	25336
@VP	are released slowly	25445
@VP	released slowly	25449
@VP	embeds the nanofilaments in the tubular scaffold	25487
@VP	are biocompatible , bioerodable , and biodegradable	25562
@VP	to create a successful implant that can replace massive segmental losses	26293
@VP	create a successful implant that can replace massive segmental losses	26296
@VP	implant that can replace massive segmental losses	26316
@VP	can replace massive segmental losses	26329
@VP	replace massive segmental losses	26333
@VP	established rich neurogenic cell cultures for implantation	26461
@VP	used in the current study bear the risk of inducing an immunogenic response	26555
@VP	inducing an immunogenic response	26598
@VP	show that neither of them evoked a rejection response	26667
@VP	evoked a rejection response	26693
@VP	cultured NOM cells of adult dogs	26809
@VP	were implanted into paralytic rats	26842
@VP	implanted into paralytic rats	26847
@VP	led to the death of animals a few days after the implantation	26895
@VP	was by no means complete	27264
@VP	implanted with the adult human NOM cells	27299
@VP	showed statistically insignificant advantages over the control group of animals	27340
@VP	being performed	27458
@VP	performed	27464
@VP	collected mixture	27641
@VP	clarify the contribution of the different adult human NOM cell-populations	27705
@VP	is an important contrast mechanism in MRI of the CNS	27916
@VP	used extensively for studying CNS pathologies and structures -LSB- 31 , 32 -RSB-	28043
@VP	studying CNS pathologies and structures -LSB- 31 , 32 -RSB-	28064
@VP	is currently also used to study fiber orientations -LSB- 31 -RSB-	28122
@VP	also used to study fiber orientations -LSB- 31 -RSB-	28135
@VP	to study fiber orientations -LSB- 31 -RSB-	28145
@VP	study fiber orientations -LSB- 31 -RSB-	28148
@VP	can be used to study CNS maturation and degeneration -LSB- 3 -RSB-	28375
@VP	be used to study CNS maturation and degeneration -LSB- 3 -RSB-	28379
@VP	used to study CNS maturation and degeneration -LSB- 3 -RSB-	28382
@VP	to study CNS maturation and degeneration -LSB- 3 -RSB-	28387
@VP	study CNS maturation and degeneration -LSB- 3 -RSB-	28390
@VP	transplanted with cell-containing composite implants	28488
@VP	imply that axonal connection was indeed established across the transplanted zone	28815
@VP	was indeed established across the transplanted zone	28844
@VP	established across the transplanted zone	28855
@VP	are underway	28918
@VP	implant for repairing spinal cord injury	29354
@VP	repairing spinal cord injury	29366
@VP	to evaluate the final outcomes of the spinal cord injured regions	29411
@VP	evaluate the final outcomes of the spinal cord injured regions	29414
@VP	injured regions	29461
@VP	brought us closer to the goal of treatment of damaged spinal cord	29498
@VP	needs to be addressed	29650
@VP	to be addressed	29656
@VP	be addressed	29659
@VP	addressed	29662
@VP	are encouraging	29687
@VP	to go before complete motor function and full gait performance are restored	29733
@VP	go before complete motor function and full gait performance are restored	29736
@VP	are restored	29796
@VP	restored	29800
